<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366091</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00047206</org_study_id>
    <secondary_id>R01HL120905</secondary_id>
    <nct_id>NCT02366091</nct_id>
  </id_info>
  <brief_title>Inflammation and Coronary Endothelial Function</brief_title>
  <official_title>Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying whether anti-inflammatory agents can improve abnormal coronary&#xD;
      artery function in patients with coronary artery disease (CAD) and abnormal coronary artery&#xD;
      endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sometimes, in patients with coronary artery disease (CAD), even though blood pressure is&#xD;
      controlled, the patients are on cholesterol medication, not smoking, eating properly and have&#xD;
      normal levels of physical activity; the investigators still see development of new blockages,&#xD;
      progression of existing blockages, and sometimes even clinical events like heart attacks and&#xD;
      strokes. Therefore, the investigators are always trying to find additional ways to decrease&#xD;
      the progression of existing blockages and to prevent new ones.&#xD;
&#xD;
      What the investigators are studying in this program is the function of the coronary arteries&#xD;
      and in particular the inner lining of the arteries called the endothelium. It has several&#xD;
      important functions; one of them is that under conditions of stress it releases a substance&#xD;
      called nitric oxide which increases the size of the artery and increases blood flow. When it&#xD;
      is not functioning normally the artery does not increase as much and blood flow does not&#xD;
      increase during stress.&#xD;
&#xD;
      The investigators study coronary artery function with magnetic resonance imaging, or MRI. MRI&#xD;
      is a method of obtaining images of what is happening inside the body. MRI does not involve&#xD;
      radiation, x-ray, and injection of contrast. The investigators can measure flow in the artery&#xD;
      and the dimension of the artery at rest and with a handgrip stress and learn the extent to&#xD;
      which the artery dilates and flow increases with the stress. The investigators believe that&#xD;
      inflammation can interfere with normal function and that by decreasing inflammation abnormal&#xD;
      endothelial function may be improved.&#xD;
&#xD;
      Methotrexate and colchicine are anti-inflammatory agents approved by the Food and Drug&#xD;
      Administration (FDA) to treat arthritis and some other conditions. These drugs are not&#xD;
      approved for use to suppress inflammation in patients with coronary artery disease and&#xD;
      improve coronary artery endothelial function. The FDA is allowing the use of methotrexate,&#xD;
      colchicine and/or their combination in this research study.&#xD;
&#xD;
      This study will involve 24 weeks of anti-inflammatory drugs and 3 Magnetic Resonance Imaging&#xD;
      (MRI) scans of the heart and other study procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Change in coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Coronary Blood Flow (CBF), Measured by MRI as the Change From Rest to IHE Stress</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Change in coronary blood flow (CBF), measured by MRI as the percent change from rest to IHE stress (as % rest) at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum High-sensitivity C Reactive Protein (Hs-CRP)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Serum high-sensitivity C reactive protein (hs-CRP), measured by laboratory assessment in mg/l at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Interleukin-6 (IL-6)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Serum interleukin-6 (IL-6), measured by laboratory assessment in pg/ml at 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial Flow Mediated Dilation (FMD)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Brachial flow mediated dilation (FMD), measured as percent brachial artery dilation by ultrasound at 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate &amp; Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Methotrexate &amp; Colchicine</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_label>Methotrexate &amp; Colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>A substance containing no medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants of either gender who are 21 years of age (no upper age limit),&#xD;
&#xD;
          -  History of prior Myocardial Infarction (MI), coronary revascularization, or coronary&#xD;
             angiography or Multidetector Computer Tomography (MDCT) demonstrating at least one&#xD;
             coronary artery with &gt;50% luminal stenosis and no plans for revascularization,&#xD;
&#xD;
          -  Clinically stable for 3 months,&#xD;
&#xD;
          -  Vascular inflammation based on elevated hsCRP (&gt;2mg L-1), or a clinical diagnosis of&#xD;
             diabetes mellitus or metabolic syndrome (metabolic syndrome is defined by three or&#xD;
             more of the following): Abdominal obesity (waist circumference: Men&gt;102 cm (&gt;40 in),&#xD;
             Women &gt;88 cm (&gt;35 in)), Serum triglycerides ≥150 mg/dL (or taking medication to treat&#xD;
             high triglycerides), HDL cholesterol: Men&lt;40 mg/dL, Women&lt;50 mg/dL (or taking&#xD;
             medication to treat low HDL cholesterol), High blood pressure: ≥130/≥85 mm Hg (or&#xD;
             taking medication to treat high blood pressure), or Fasting glucose: ≥100 mg/dL (or&#xD;
             taking medication to treat high fasting glucose).&#xD;
&#xD;
          -  Abnormal Coronary Endothelial Function (CEF) (change in CSA during IHE of &lt;0% of the&#xD;
             resting value: by this we mean any decrease in CSA or no change (0%) from baseline&#xD;
             during IHE),&#xD;
&#xD;
          -  Permission of patient's clinical attending physician,&#xD;
&#xD;
          -  Patients being treated with a statin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to understand the risks, benefits, and alternatives of participation&#xD;
             and give meaningful consent,&#xD;
&#xD;
          -  Patients with contraindications to MRI such as implanted metallic objects&#xD;
             (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,&#xD;
&#xD;
          -  Acute coronary syndrome within the prior three months,&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  Contraindications to methotrexate or colchicine as outlined by the American College of&#xD;
             Rheumatology; including active bacterial infection, tuberculosis, or herpes zoster&#xD;
             infection, leukopenia (&lt;4000/mm3), thrombocytopenia (&lt;135,000/mm3), elevation in&#xD;
             hepatic transaminases (&gt;2x upper limit of normal), hepatitis B or C, moderate renal&#xD;
             disease (estimated creatine clearance &lt;45ml/min), or planned surgery,&#xD;
&#xD;
          -  Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative&#xD;
             colitis or Crohn's disease,&#xD;
&#xD;
          -  Interstitial lung disease or pulmonary fibrosis,&#xD;
&#xD;
          -  HIV positive,&#xD;
&#xD;
          -  Requirement for, or intolerance to, methotrexate or colchicine ,&#xD;
&#xD;
          -  Intolerance to methotrexate, colchicine or folate,&#xD;
&#xD;
          -  History of non-basal cell malignancy or treatment for lymphoproliferative disease in&#xD;
             the past 5 years,&#xD;
&#xD;
          -  Requirement for use of drugs that alter folate metabolism,&#xD;
&#xD;
          -  History of alcohol abuse or unwillingness to limit consumption to &lt; 4 drinks per week,&#xD;
&#xD;
          -  Women of childbearing potential or intention to breastfeed.&#xD;
&#xD;
          -  Men who plan to father children during the study period; men who have sexual&#xD;
             intercourse with women of childbearing potential must agree to use a condom,&#xD;
&#xD;
          -  Chronic use of oral or IV steroid therapy or other immunosuppressive or biologic&#xD;
             response modifiers,&#xD;
&#xD;
          -  History of chronic pericardial effusion, pleural effusion or ascites,&#xD;
&#xD;
          -  New York Heart Association Class IV heart failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug;166(2):199-207.e15. doi: 10.1016/j.ahj.2013.03.018. Epub 2013 May 3.</citation>
    <PMID>23895801</PMID>
  </reference>
  <reference>
    <citation>Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19.</citation>
    <PMID>23265346</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Hirsch GA, Kelle S, Gerstenblith G, Weiss RG, Stuber M. Noninvasive visualization of coronary artery endothelial function in healthy subjects and in patients with coronary artery disease. J Am Coll Cardiol. 2010 Nov 9;56(20):1657-65. doi: 10.1016/j.jacc.2010.06.036.</citation>
    <PMID>21050976</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Stuber M, Hirsch GA, Yu J, Schär M, Weiss RG, Gerstenblith G, Kelle S. Non-invasive detection of coronary endothelial response to sequential handgrip exercise in coronary artery disease patients and healthy adults. PLoS One. 2013;8(3):e58047. doi: 10.1371/journal.pone.0058047. Epub 2013 Mar 11.</citation>
    <PMID>23536782</PMID>
  </reference>
  <reference>
    <citation>Hays AG, Kelle S, Hirsch GA, Soleimanifard S, Yu J, Agarwal HK, Gerstenblith G, Schär M, Stuber M, Weiss RG. Regional coronary endothelial function is closely related to local early coronary atherosclerosis in patients with mild coronary artery disease: pilot study. Circ Cardiovasc Imaging. 2012 May 1;5(3):341-8. doi: 10.1161/CIRCIMAGING.111.969691. Epub 2012 Apr 5.</citation>
    <PMID>22492483</PMID>
  </reference>
  <reference>
    <citation>Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med. 1990 Dec 6;323(23):1593-600.</citation>
    <PMID>2233948</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02366091/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>17 enrolled participants were excluded from the study prior to randomization as follows: 9 did not qualify by screening MRI; 3 did not qualify by lab work; 3 declined to proceed after qualifying by MRI; 2 were not randomized as enrollment target was met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methotrexate</title>
          <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="P2">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="P3">
          <title>Methotrexate &amp; Colchicine</title>
          <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methotrexate</title>
          <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="B2">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="B3">
          <title>Methotrexate &amp; Colchicine</title>
          <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" lower_limit="56.7" upper_limit="68.7"/>
                    <measurement group_id="B2" value="66.8" lower_limit="56.2" upper_limit="67.9"/>
                    <measurement group_id="B3" value="63.4" lower_limit="56.9" upper_limit="70.7"/>
                    <measurement group_id="B4" value="63.9" lower_limit="55.9" upper_limit="69.5"/>
                    <measurement group_id="B5" value="63.77" lower_limit="56.23" upper_limit="69.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</title>
        <description>Coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</title>
          <description>Coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 8 weeks.</description>
          <units>Percent change from rest measurement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="2.85"/>
                    <measurement group_id="O2" value="2.71" spread="3.74"/>
                    <measurement group_id="O3" value="-0.39" spread="2.23"/>
                    <measurement group_id="O4" value="2.04" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</title>
        <description>Change in coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 24 weeks.</description>
        <time_frame>At 24 weeks</time_frame>
        <population>Not all participants who completed the primary outcome at 8 weeks went on to complete the 24 week studies, resulting in different numbers of participants analyzed between weeks 8 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE)</title>
          <description>Change in coronary segment endothelial function, measured by MRI as the percent change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest) at 24 weeks.</description>
          <population>Not all participants who completed the primary outcome at 8 weeks went on to complete the 24 week studies, resulting in different numbers of participants analyzed between weeks 8 and 24.</population>
          <units>Percent change from rest measurement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="3.36"/>
                    <measurement group_id="O2" value="-5.39" spread="3.91"/>
                    <measurement group_id="O3" value="2.64" spread="2.60"/>
                    <measurement group_id="O4" value="9.26" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Coronary Blood Flow (CBF), Measured by MRI as the Change From Rest to IHE Stress</title>
        <description>Change in coronary blood flow (CBF), measured by MRI as the percent change from rest to IHE stress (as % rest) at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Coronary Blood Flow (CBF), Measured by MRI as the Change From Rest to IHE Stress</title>
          <description>Change in coronary blood flow (CBF), measured by MRI as the percent change from rest to IHE stress (as % rest) at 8 weeks.</description>
          <units>Percent change from rest measurement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="4.70"/>
                    <measurement group_id="O2" value="14.06" spread="4.57"/>
                    <measurement group_id="O3" value="12.38" spread="5.58"/>
                    <measurement group_id="O4" value="13.81" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum High-sensitivity C Reactive Protein (Hs-CRP)</title>
        <description>Serum high-sensitivity C reactive protein (hs-CRP), measured by laboratory assessment in mg/l at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum High-sensitivity C Reactive Protein (Hs-CRP)</title>
          <description>Serum high-sensitivity C reactive protein (hs-CRP), measured by laboratory assessment in mg/l at 8 weeks.</description>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.54"/>
                    <measurement group_id="O2" value="3.10" spread="1.68"/>
                    <measurement group_id="O3" value="1.45" spread="0.22"/>
                    <measurement group_id="O4" value="1.65" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Interleukin-6 (IL-6)</title>
        <description>Serum interleukin-6 (IL-6), measured by laboratory assessment in pg/ml at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Interleukin-6 (IL-6)</title>
          <description>Serum interleukin-6 (IL-6), measured by laboratory assessment in pg/ml at 8 weeks.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.55"/>
                    <measurement group_id="O2" value="1.20" spread="0.27"/>
                    <measurement group_id="O3" value="0.83" spread="0.07"/>
                    <measurement group_id="O4" value="0.92" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Flow Mediated Dilation (FMD)</title>
        <description>Brachial flow mediated dilation (FMD), measured as percent brachial artery dilation by ultrasound at 8 weeks.</description>
        <time_frame>At 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
          <group group_id="O3">
            <title>Methotrexate &amp; Colchicine</title>
            <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Flow Mediated Dilation (FMD)</title>
          <description>Brachial flow mediated dilation (FMD), measured as percent brachial artery dilation by ultrasound at 8 weeks.</description>
          <units>percent brachial artery dilation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="0.70"/>
                    <measurement group_id="O2" value="3.23" spread="0.52"/>
                    <measurement group_id="O3" value="3.58" spread="0.48"/>
                    <measurement group_id="O4" value="4.57" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over study enrollment and up to 4 weeks after the last dose of the study drug (total up to 28 weeks after initiation of study drug).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methotrexate</title>
          <description>Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="E2">
          <title>Colchicine</title>
          <description>Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
        <group group_id="E3">
          <title>Methotrexate &amp; Colchicine</title>
          <description>Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily&#xD;
Methotrexate: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease&#xD;
Colchicine: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily&#xD;
Placebo: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization for unstable angina/chest pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hopsitalization</sub_title>
                <description>Hospitalization for transient bilateral vision loss.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization for shoulder pain</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization for pulmonary symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased White Blood Cell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Decreased Hematocrit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Alanine Amino Trans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Increased Aspartate Amino Trans &gt;3 x the normal range</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dental pain/infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Physical Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/Muscle Soreness/Stiffness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Estimated GFR</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert G. Weiss, MD</name_or_title>
      <organization>Johns Hopkins Hospital</organization>
      <phone>410-955-1703</phone>
      <email>rweiss@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

